HARBIN, China, Sept. 3 China Sky OneMedical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), aleading fully integrated pharmaceutical company producing over-the-counterdrugs in the People's Republic of China ("PRC"), today announced that theCompany has finished the required research for two new generic drugs for eyetreatment and submitted application to the State Food and Drug Administration(SFDA) in China to perform clinical trials.
Compound Allantoin Vitamin B-E and Aminoethylsulfonic Acid eye drops areused to cure chronic conjunctivitis, cornea trauma and congestive conjunctiva.Dextran and Glycerol eye drops are used to eliminate dryness, sharp pain, andother irritation of the eye. Currently there are no domestic pharmaceuticalcompanies in China that are able to produce Dextran and Glycerol eye drops.Both eye products represent the latest medical technology available worldwideand the Company believes they have promising market potential.
"We are excited to have made such great progress in our research and lookforward to receiving SFDA approval for the production of both of our eyeproducts within two years," commented Mr. Yan-qing Liu, Chairman and CEO ofChina Sky One Medical. "We are fully committed to increasing our drugportfolio by bringing quality new products into the Chinese market."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.The Company engages in the manufacturing, marketing and distribution ofpharmaceutical, medicinal and diagnostic products. Through its wholly-ownedsubsidiaries, Harbin Tian Di Ren Medical Science and Technology Company("TDR"), Harbin First Bio-Engineering Company Limited ("First"), HeilongjiangTianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin ChuangPharmaceutical Company ("Jin Chuang") the Company manufactures and distributesover-the-counter pharmaceutical products, which make up its major revenuesource. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward-looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risks anduncertainties and may include financial projections or information regardingthe progress of new product development. Actual results could differmaterially from the expectations reflected in such forward-looking statementsas a result of a variety of factors, including the risks associated with theeffect of changing economic conditions in The People's Republic of China,variations in cash flow, reliance on collaborative retail partners and on newproduct development, variations in new product development, risks associatedwith rapid technological change, and the potential of introduced or undetectedflaws and defects in products, and other risk factors detailed in reportsfiled with the Securities and Exchange Commission from time to time.For more information, please contact: Company Contact: China Sky One Medical, Inc. Mr. Stanley Hao, CFO Tel: +86-0451-5399 x4069 Email: firstname.lastname@example.org Investor Relations Contact: CCG Investor Relations Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: email@example.com Web: http://www.ccgirasia.com
SOURCE China Sky One Medical, Inc.